Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H11NO2 |
| Molecular Weight | 201.2212 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN(C(=O)C=C1)C2=CC=C(O)C=C2
InChI
InChIKey=NETTXQJYJRFTFS-UHFFFAOYSA-N
InChI=1S/C12H11NO2/c1-9-2-7-12(15)13(8-9)10-3-5-11(14)6-4-10/h2-8,14H,1H3
| Molecular Formula | C12H11NO2 |
| Molecular Weight | 201.2212 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
F-351 (Hydronidone), a pyridine derivative, is a non-steroidal antiinflammatory drug. It inhibits hepatic stellate cell proliferation and also the TGF-β signaling pathway. Shanghai Genomics is developing F-351 for the treatment of liver fibrosis induced by HBV chronic hepatitis (HBV). For additional indications, F-351 has the potential to be further developed for Non-alcoholic steatohepatitis (NASH) liver disease, Non-alcoholic fatty liver disease (NAFLD) and chronic kidney failure.
Originator
Approval Year
Sample Use Guides
A randomized, dose-escalating, first-in-human study was conducted in 88 subjects. Five cohorts of 34 subjects received a single dose of hydronidone capsules at 15-120 mg, and two cohorts of 12 subjects received 90 and 120 mg of hydronidone thrice daily for 7 days, and six subjects received 60 mg of hydronidone thrice daily for 28 days to assess the safety and tolerability. In 36 subjects, hydronidone pharmacokinetics were investigated following oral administration of single (30, 60, and 120 mg) and multiple (60 mg, thrice daily) doses of hydronidone.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:53:17 GMT 2023
by
admin
on
Sat Dec 16 02:53:17 GMT 2023
|
| Record UNII |
RXQ128313W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11217901
Created by
admin on Sat Dec 16 02:53:17 GMT 2023 , Edited by admin on Sat Dec 16 02:53:17 GMT 2023
|
PRIMARY | |||
|
DB06299
Created by
admin on Sat Dec 16 02:53:17 GMT 2023 , Edited by admin on Sat Dec 16 02:53:17 GMT 2023
|
PRIMARY | |||
|
RXQ128313W
Created by
admin on Sat Dec 16 02:53:17 GMT 2023 , Edited by admin on Sat Dec 16 02:53:17 GMT 2023
|
PRIMARY | |||
|
DTXSID40459058
Created by
admin on Sat Dec 16 02:53:17 GMT 2023 , Edited by admin on Sat Dec 16 02:53:17 GMT 2023
|
PRIMARY | |||
|
851518-71-3
Created by
admin on Sat Dec 16 02:53:17 GMT 2023 , Edited by admin on Sat Dec 16 02:53:17 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Drug: Hydronidone; Indication: Hepatic fibrosis; Focus: Therapeutic Use; Sponsor: Shanghai Genomics; Most Recent Event: 21 Jul 2015 New trial record
|
||
|
ACTIVE MOIETY |
The U.S. Food and Drug Administration (FDA) is warning about several safety issues with the entire class of opioid pain medicines. These safety risks are potentially harmful interactions with numerous other medications, problems with the adrenal glands, and decreased sex hormone levels. We are requiring changes to the labels of all opioid drugs to warn about these risks.
|
||
|
ACTIVE MOIETY |
ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm for a complete listing. These safety risks are potentially harmful interactions with numerous other medications, problems with the adrenal glands, and decreased sex hormone levels. We are requiring changes to the labels of all opioid drugs to warn about these risks.
|
